Free Newsletter
Stupak: FDA needs subpoena power
Rep. Bart Stupak (photo) might be a severe FDA critic, but he's also shaping up to be the agency's dearest friend. Chief of the House Energy and Commerce committee's oversight-and-investigations group, Stupak helped push FDA commissioner Andrew von Eschenbach to ask for millions more in FDA funding--and now he's suggesting that the FDA needs subpoena power. That's no small thing; it would allow the FDA to demand documents from drugmakers rather than simply ask nicely and say please.
Apparently, Democrats on the committee have been rankled by the FDA's lack of power in that department because they think it has limited the agency's pharma investigations. During a recent hearing, Stupak asked CDER honcho Janet Woodcock and her deputy whether they'd like subpoena power; they agreed it would be "very useful." Now, Stupak has written to von Eschenbach asking his opinion on the potential change. He'd like to add it to a drug importation bill now pending in the House. No word on what the commish plans to say in response.
- read the WSJ Health Blog item
Related Articles:
Stupak plays bad cop against pharma
The FDA's surprising plea for cash
FDA backpedals on inspection funding
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: